Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The biliary tract cancers market was valued at USD 609.10 Billion in 2025 and is expected to grow at a CAGR of 6.10%, reaching USD 1101.14 Billion by 2035. The market growth is driven by the increasing need for effective treatments, including targeted therapies, immunotherapies, and chemotherapy. The development of precision medicine, biomarker-based patient selection, and novel drug candidates is expected to expand treatment options, improve clinical outcomes, and support market growth during the forecast period.

Key Market Trends and Insights

  • By drug class, targeted therapy is projected to account for nearly 60% of the market in the forecast period.
  • Based on route of administration, intravenous is expected to lead the market in the forecast period.
  • By distribution channel, hospital pharmacies are projected to witness significant growth in the forecast period.

Market Size and Forecast

  • Market Size (2025): USD 609.10 Billion
  • Projected Market Size (2035): USD 1101.14 Billion
  • CAGR (2026-2035): 6.10%

Compound Annual Growth Rate

6.1%

Value in USD Billion

2026-2035


Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Biliary Tract Cancers Market Overview

Biliary tract cancers are a group of malignancies affecting the bile ducts, gallbladder, and ampulla of Vater. These cancers often present with nonspecific symptoms and are frequently diagnosed at advanced stages, creating challenges for timely detection and effective treatment. Disease progression, limited early detection, and variable treatment outcomes contribute to the clinical burden. The market is shaped by the rising need for effective diagnostic and therapeutic approaches, including surgery, chemotherapy, targeted therapies, and immunotherapy. Advances in molecular profiling and biomarker identification are supporting more personalized treatment strategies. The market is poised to grow at a CAGR of 6.10% during the forecast period of 2026-2035. Ongoing clinical research, new drug development, and regulatory approvals are expanding therapeutic options, while high treatment costs, late diagnosis, and limited treatment efficacy in advanced disease remain key challenges.

Biliary Tract Cancers Market Growth Analysis and Key Influencers

Analysis Type

Factors

Example

Market Drivers

Growing Adoption of Combination Immunotherapy

AstraZeneca's durvalumab and chemotherapy combination received approval in India in February 2023 after the TOPAZ-1 trial showed survival benefits in advanced biliary tract cancer.

Market Restraints

Aggressive Disease Progression and Therapeutic Limitations

Late diagnosis, restricted eligibility for curative surgery, and treatment-related side effects complicate patient care and limit the effectiveness of available treatment approaches.

Market Opportunities

Development of Dual-Targeted Cancer Therapies

In October 2026, a collaboration involving Akeso, Summit Therapeutics, and ECOG-ACRIN advanced plans to investigate ivonescimab alongside chemotherapy for advanced biliary tract cancer.

Biliary Tract Cancers Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Biliary Tract Cancers Market Growth Drivers

Advancements in Immunotherapy Strengthen the Market Value

The increasing adoption of immunotherapy combined with chemotherapy is supporting the expansion of the market by improving treatment outcomes for patients with advanced disease. These combination therapies offer additional options for patients with limited treatment alternatives and poor prognoses. For instance, in February 2023, AstraZeneca announced that India's Central Drugs Standard Control Organization (CDSCO) had approved durvalumab in combination with chemotherapy for locally advanced or metastatic biliary tract cancer. The TOPAZ-1 trial demonstrated improved overall survival, supporting demand for advanced treatment options.

Biliary Tract Cancers Market Restraints

Poor Prognosis and Limited Treatment Options Challenge the Market Expansion

The frequent diagnosis of biliary tract cancer at an advanced stage, combined with its aggressive nature, presents a significant challenge to market growth. Limited opportunities for curative surgery and the need for more effective treatments complicate disease management. Treatment-related adverse reactions and the need for careful patient monitoring can also increase the complexity of care. These factors may restrict treatment effectiveness and complicate the broader adoption of newer therapies across patient populations.

Biliary Tract Cancers Market Opportunities

Advancing Bispecific Antibody Therapies Could Expand the Market Landscape

The development of innovative immunotherapies creates potential for improved treatment outcomes and broader therapeutic options for patients with advanced biliary tract cancer. Therapies that simultaneously target multiple cancer-related pathways may offer advantages over existing treatment approaches. For instance, in October 2026, Akeso announced a collaboration involving Summit Therapeutics and the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab with chemotherapy in a Phase II/III trial for first-line treatment of advanced biliary tract cancer. This clinical development could support future treatment innovation and market expansion, subject to trial results and regulatory approval.

Biliary Tract Cancers Market Trends

Some notable trends in the market include personalized medicine, genomic profiling, and the development of targeted combination therapies.

Increasing Adoption of Precision Medicine Is Likely to Support Market Growth

Precision medicine is gaining importance in biliary tract cancer treatment as genomic profiling helps identify tumor-specific targets and guide therapy selection. This approach may improve treatment personalization and expand the role of targeted therapies alongside established treatment regimens. For instance, in January 2025, University College London (UCL) announced the opening of the SAFIR-ABC10 trial, which uses genetic profiling to match patients with biliary tract cancer to selected anticancer therapies. These advances could support more individualized treatment strategies and contribute to market growth.

Biliary Tract Cancers Market Share

Intravenous Administration Is Expected to Lead the Market by Route of Administration

The market is segmented by route of administration into oral and intravenous formulations. The intravenous segment is expected to lead because several established treatment regimens for advanced biliary tract cancer rely on infused chemotherapy and immunotherapy, enabling the administration of combination treatments under clinical supervision. For instance, in October 2023, Merck announced that the US Food and Drug Administration (FDA) had approved pembrolizumab in combination with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. The regimen is administered through intravenous infusion, supporting demand for this route.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Biliary Tract Cancers Market Analysis by Region

The regions included in the report are the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to remain a leading market, supported by clinical research activity, established oncology infrastructure, and the development of innovative treatment options. For instance, in October 2026, the ECOG-ACRIN Cancer Research Group announced a US Phase II/III trial evaluating ivonescimab with chemotherapy against standard chemoimmunotherapy for advanced biliary tract cancer. This research activity could strengthen treatment development and support market growth in the United States.

Leading Players in the Biliary Tract Cancers Market

The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by leading players. The major companies in the market are as follows:

Incyte Corporation

Incyte Corporation is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies for unmet medical needs. Its product, Pemazyre (pemigatinib), is a selective fibroblast growth factor receptor (FGFR) inhibitor approved for previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The company contributes to the market through targeted treatment development.

Servier Pharmaceuticals LLC

Servier Pharmaceuticals LLC is involved in the market through TIBSOVO (ivosidenib), a targeted therapy for adults with previously treated, advanced cholangiocarcinoma harboring an isocitrate dehydrogenase-1 (IDH1) mutation. The oral treatment is designed to slow disease progression by targeting the specific mutation, providing a treatment option for eligible patients whose cancer has spread.

Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Co., Ltd. is a pharmaceutical company involved in the biliary tract cancer market through LYTGOBI (futibatinib), an oral, selective, irreversible FGFR inhibitor. In June 2023, the company received approval in Japan to manufacture and market LYTGOBI for unresectable biliary tract cancer with FGFR2 gene fusions that progressed after chemotherapy. The product expands targeted treatment options for eligible patients.

Merck & Co., Inc.

Merck & Co., Inc. is involved in the biliary tract cancer market through KEYTRUDA (pembrolizumab), an immunotherapy used in combination with gemcitabine and cisplatin to treat patients with locally advanced unresectable or metastatic biliary tract cancer. The treatment combines PD-1 inhibition with chemotherapy and has demonstrated an overall survival benefit compared with chemotherapy alone in clinical trials.

Other key players in the market include F. Hoffmann-La Roche Ltd. and AstraZeneca PLC.

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Biliary Tract Cancers Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

  • Targeted Therapy
  • Chemotherapy
  • Immune Checkpoint Inhibitor
  • Others

The market is influenced by ongoing advances in cancer treatment, increasing understanding of tumor biology, and the development of therapies targeting specific molecular pathways. Growing emphasis on personalized treatment strategies and improved clinical outcomes supports demand for diverse pharmacological approaches to biliary tract cancers.

Market Breakup by Route of Administration

  • Oral
  • Intravenous

Treatment delivery preferences are shaped by disease stage, patient condition, therapeutic requirements, and treatment protocols. Advances in oncology care and efforts to improve treatment adherence, clinical effectiveness, and patient convenience influence the use of different administration approaches in biliary tract cancer management.

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

The distribution landscape is shaped by the need for reliable access to oncology medicines, specialized handling of certain therapies, and coordination among healthcare providers and suppliers. Hospital-based treatment, prescription fulfillment, and the growing use of digital healthcare services influence medicine procurement and availability.

Market Breakup by End User

  • Hospitals and Clinics
  • Specialty Cancer Centers
  • Homecare Settings
  • Others

Demand across healthcare settings is influenced by the complexity of biliary tract cancer diagnosis and treatment, the need for multidisciplinary oncology teams, and access to specialized diagnostic and therapeutic services. Continued improvements in cancer care infrastructure and supportive services also shape treatment delivery and patient management.

Market Breakup by Country

  • United States
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Japan
  • India

The market reflects differences in cancer incidence, healthcare infrastructure, reimbursement policies, access to innovative oncology medicines, and national treatment guidelines. Research investment, regulatory frameworks, and the availability of specialized cancer care services further influence the adoption of biliary tract cancer therapies across individual markets.

Key Questions Answered in the Biliary Tract Cancers Market Report

  • What was the biliary tract cancers market value in 2025?
  • What is the biliary tract cancers market forecast outlook for 2026-2035?
  • What are the major factors aiding the biliary tract cancers market demand?
  • How has the market performed so far, and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • What are the major biliary tract cancers market trends?
  • Which drug class is expected to dominate the market segment?
  • Which route of administration is projected to lead the market segment?
  • Which distribution channel is anticipated to drive the market segment?
  • Which end user is likely to dominate the market segment?
  • Who are the key players involved in the biliary tract cancers market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed using a robust mixed-methods research approach combining primary and secondary research to assess the biliary tract cancers market across eight major markets.

  • Primary Research: Expert consultations with oncologists, hepatobiliary specialists, oncology procurement managers, and payer representatives to understand treatment patterns, unmet needs, prescribing practices, and market access dynamics.
  • Secondary Research: Analysis of peer-reviewed publications, clinical trial records from ClinicalTrials.gov, regulatory information from the US FDA, European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and India’s Central Drugs Standard Control Organization (CDSCO), alongside epidemiological information from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH). Company websites and product information are also reviewed to assess drug portfolios, pipeline developments, and strategic initiatives.
  • Validation: Market estimates and forecasts are assessed through top-down and bottom-up modeling, cross-checked against available epidemiological, clinical, regulatory, and company-level data, with expert validation where applicable.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2025
Historical Period 2019-2025
Forecast Period 2026-2035
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Route of Administration
  • Distribution Channel
  • End User
  • Region
Breakup by Drug Class
  • Targeted Therapy
  • Chemotherapy
  • Immune Checkpoint Inhibitor
  • Others
Breakup by Route of Administration
  • Oral
  • Intravenous
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
Breakup by End User
  • Hospitals and Clinics
  • Specialty Cancer Centers
  • Homecare Settings
  • Others
Breakup by Region
  • United States
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Incyte Corporation
  • Servier Pharmaceuticals LLC
  • Taiho Pharmaceutical Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • AstraZeneca PLC

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us